Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
Michael Untch, Peter Andreas Fasching, Gottfried E. Konecny et al. · Journal of Clinical Oncology · 2011
PURPOSE: To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. PATIENTS AND METHODS: Patients with centrally confirmed HER2-overexpressing breast cancer (≥ 2 cm or inflammatory) received four 3-week cycles epirubicin and cyclophosphamide (90/600 mg/m(2)) followed by four 3-week cycles paclitaxel (175 mg/m(2)) and trastuzumab (6 mg/kg) before surgery. Trastuzumab was continued after surgery to complete 1 year of treatment. Primary end point was pathologic complete response (pCR) defined as no residual invasive tumor in breast and lymphatic tissue. RESULTS: Thirty-nine percent of 217 enrolled patients achieved a pCR. Breast conservation was possible in 64% of patients. Three-year disease-free survival (DFS) was 88% in patients with pCR compared to 73% in patients without pCR (P = .01). Three-year overall survival (OS) was 96% in patients with pCR compared to 86% in patients without pCR (P = .025). pCR was the only significant prognostic factor for DFS (hazard ratio [HR] 2.5; 95% CI, 1.2 to 5.1; P = .013) and OS (HR, 4.9; 95% CI, 1.4 to 17.4; P = .012) in multivariable analysis. Cardiac toxicity was reported in eight patients (3.7%) of whom six presented with an asymptomatic left ventricular ejection fraction decrease and two with symptomatic chronic heart failure. CONCLUSION: Neoadjuvant combination of trastuzumab and chemotherapy resulted in a high pCR rate in HER2-overexpressing primary breast cancer. Patients with a pCR after neoadjuvant anti-HER2 therapy in combination with chemotherapy followed by maintenance trastuzumab have an improved long-term outcome. Patients without a pCR had an increased risk for relapse and death.
Cited by 506 works. doi:10.1200/jco.2010.31.4930
Authors
- Michael Untch
- Peter Andreas Fasching
- Gottfried E. Konecny
- Stephan Hasmüller
- Annette Lebeau
- R. Kreienberg
- Oumar Camara
- Volkmar Müller
- Andreas du Bois
- Thorsten Kühn
- Elmar Stickeler
- Nadia Harbeck
- Cornelia Höß
- Steffen Kahlert
- THOMAS M. BECK
- Werner Fett
- Keyur M. Mehta
- Gϋnter von Minckwitz
- Sibylle Loibl
References
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy